FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

The FDA approved Zolinza capsules for the treatment of cutaneous T-cell lymphomalymphoma, a lymphoma that affects the skin. The FDA, in a news release, said the drug was approved to use when the disease worsens, is persistent or returns after treatment with other drugs.

About 3 in 1 million people, mainly middle-aged men, are diagnosed with CTCL each year, the FDA said.

The FDA said it approved Zolinza as part of its Orphan Drug program, which offers companies financial incentives to develop medicines for diseases and conditions affecting fewer than 200,000 people in the United States a year.

Zolinza is manufactured by Pantheon Inc. for Merck & Co. Inc., the FDA said.

Copyright 2006 by United Press International

Explore further: Researchers provide insights for reducing drug overdoses through community education

add to favorites email to friend print save as pdf

Related Stories

Tuning light to kill deep cancer tumors

Oct 15, 2014

An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set ...

Recommended for you

Generic form of nexium approved

Jan 26, 2015

(HealthDay)—The first generic version of the heartburn drug Nexium (esomeprazole) has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.